Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Donor NK Cell Therapy + ALT-803 in Cancer
NCT02890758Phase 1Completed
- Start
- May 2018
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Natural Killer Cells and nogapendekin alfa inbakicept in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 11 more (2 arms). Primary endpoints: Maximum Tolerated Dose at 28 days and Number of participants without Graft Versus Host Disease at 28 days. Started May 2018; status: completed.
02
Drugs
Natural Killer Cellsnogapendekin alfa inbakicept
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02890758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890758.